COVID-19 IgM/IgG rapid detection

Biomedical omics has developed and launched the world’s first rapid lateral flow immunoassay for diagnosis of coronavirus infection. The Chinese Center for Disease Control and Prevention has widely used the test to fight infections, and it is now available worldwide. This test detects early markers and late markers, IgM/IgG antibodies in human finger puncture (capillary) or venous whole blood, serum and plasma samples.

It can be used to quickly screen symptomatic or asymptomatic virus carriers. Recent studies have shown that most patients have no clinical symptoms, so screening patients is essential. The test is very suitable for hospitals, clinics and test laboratories. The test can also be effectively applied to enterprises, schools, airports, seaports, and railway stations.

Features and benefits

Using Covid19's IgM-IgG combined antibody rapid detection technology, qualitative detection of IgG and IgM antibodies of novel coronavirus in human serum, plasma or whole blood in vitro.

1. Precise:

Suitable for whole blood, serum and plasma

Detection of IgM and IgG antibodies

Verify with PCR

2. Quick

10-15 minutes per test

Intuitive vision

No special equipment required